San Diego-based Viking Therapeutics marked alone as a serious competitor inside the weight loss drug market in February after revealing promising data from the mid-stage demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the company unveiled progra